- Algernon Pharmaceuticals (AGN) subsidiary Algernon NeuroScience has completed dosing of the first cohort in its Phase 1 clinical study of DMT’s intravenous formulation of AP-188
- The company reports that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues
- There will be up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects
- Algernon Pharmaceuticals (AGN) was up 1.52 per cent, trading at C$2.00 per share as of 1 pm ET
Algernon Pharmaceuticals (AGN) subsidiary Algernon NeuroScience has completed dosing of the first cohort.
The company completed dosing of the first cohort in its Phase 1 clinical study of DMT’s intravenous formulation of AP-188.
AP-188 (N,N-Dimethyltryptamine or DMT) is a known psychedelic compound that is part of the tryptamine family.
The company reports that the safety review committee has approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues.
The trial is being conducted at the Centre for Human Drug Research (CHDR) in Leiden, Netherlands. There will be up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects.
The purpose of the Phase 1 study was to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion for durations which have never been studied clinically.
According to the company, generated data will help plan a Phase 2 acute stroke and rehabilitation study more effectively.
“We are very pleased by the progress made by CHDR, as well as with the safety profile of DMT observed at this stage in our Phase 1 study,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Although DMT has been previously investigated in humans, we are breaking new ground in this study in terms of both the length of the infusion and the frequency of exposure.”
Algernon NeuroScience is a private equity subsidiary of Algernon Pharmaceuticals Inc. (AGN) and has been created to advance the company’s DMT stroke research program.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development and repurposing company investigating multiple drugs for unmet global medical needs.
Algernon Pharmaceuticals (AGN) was up 1.52 per cent, trading at C$2.00 per share at 1.00 pm ET.
